Crossmark

Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study

Crossref DOI link: https://doi.org/10.1007/s40273-021-01057-y

Published Online: 2021-06-19

Published Print: 2021-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pennington, Becky https://orcid.org/0000-0002-1002-022X
Alshreef, Abualbishr https://orcid.org/0000-0003-2737-1365
Flight, Laura https://orcid.org/0000-0002-9569-8290
Metry, Andrew https://orcid.org/0000-0001-7412-6093
Poku, Edith

Hykin, Philip

Sivaprasad, Sobha

Prevost, A. Toby https://orcid.org/0000-0003-1723-0796
Vasconcelos, Joana C.

Murphy, Caroline

Kelly, Joanna

Yang, Yit

Lotery, Andrew https://orcid.org/0000-0001-5541-4305
Williams, Michael

Brazier, John
License Information

Text and Data Mining valid from 2021-06-19

Version of Record valid from 2021-06-19
More Information

Article History

First Online: 19 June 2021